key: cord-0897528-gnkfplzn
authors: Risch, Harvey A
title: Response to: “Overcoming the therapeutic nihilism of out-of-hospital management of COVID-19 patients”
date: 2020-12-16
journal: Am J Epidemiol
DOI: 10.1093/aje/kwaa275
sha: 2db874963f28cd5c1d4fb210eaae522b9dc74198
doc_id: 897528
cord_uid: gnkfplzn

nan

international medical-records databases of older rheumatoid arthritis patients, no significant differences were seen in all-cause mortality between patients who did or did not use HCQ (10, 11) . The Oxford investigators also looked at cardiac arrhythmias and their data show no increases among the more than 900,000 HCQ users (11) . This fact is completely consistent with the established medical literature for HCQ (12) .

The common consensus of physicians who actually treat COVID-19 outpatients, as opposed to ivory-tower academics and other doctors who treat hospitalized patients and have no experience with outpatients, is an immediate, staged, multi-drug approach (13) very similar to the one outlined by Dr. Meini. Outpatient treatment is not "all about HCQ," it is finding the combination and sequence of medications that is optimal for the specific patient. In delivering this care, physicians must be able to recommend and patients free to choose courses of treatment from within all approved medications, based on best available applicable evidence, without the absurd, money-driven corrupted meddling and restrictions of government bureaucracies as suffered in many of the western nations (14) . 

Overcoming the therapeutic nihilism of out-of-hospital management of COVID-19 patients

The Media Sabotage of Hydroxychloroquine Use for COVID-19: Doctors Worldwide Protest the Disaster. Media and Big Pharma are in lockstep to suppress a cheap, life-saving Covid-19 therapy in order to reap pandemic-sized profits

Therapeutic Management of Patients with COVID-19

Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19

Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. Preprints

Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis

The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: A nationwide prospective cohort study

Early treatment with hydroxychloroquine: a country-based analysis

HCQ is effective for COVID-19 when used early: analysis of 150 studies

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study

Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped up immediately as key to the pandemic crisis

Cardiac complications attributed to hydroxychloroquine: A systematic review of the literature pre-COVID-19

Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection

Gilead: Twenty-one billion reasons to discredit hydroxychloroquine